neurocrin partner cover chri raymond receiv fda approv
orilissa elagolix women moderate-to-sever pain associ endometriosi
believ label read favor particularli consid fda gave bless
essenti chronic dose lower mg once-daili dose
month treatment requir bmd monitor view label
languag regard hepat safeti rel innocu attract royalti stream
orilissa endometriosi eventu uterin fibroid along like continu
aggress growth ingrezza view well posit transform
earn growth ep compound-annual-growth-rate translat attract
risk/reward profil price-to-earnings reiter ow rais pt
owe lower discount rate use pt calcul
chronic dose rel innocu label languag regard bmd
hepat safeti recommend dose per label mg daili qd
month mg twice-daili bid month patient normal liver
function mild hepat impair mg qd month patient
moder hepat impair notabl label requir period monitor
liver function label also requir period monitor bmd though
stronger languag would problemat view given bone
scan gener cumbersom uncommon among pre- post-
menopaus women surmis signific major patient ultim
lower mg qd dose given show clear efficaci pivot
studi superior versu placebo daili non-menstru pelvic pain daili
dysmenorrhea menstrual pain month refer note
detail given impact bmd hepat function highli limit
 rate bmd declin spine hip femor neck greater
dose less two pivot studi respect
patient mg qd dose liver enzym elev least upper
limit normal compar patient placebo
thought payer landscap orilissa initi list price
approxim per monthli prescript mg qd mg bid
dose surmis product heavili contract given larg size
underli market specter signific label expans uterin fibroid put
anoth way make sens contract aggress order drive hassle-
free access context larg patient popul alreadi engag
direct-to-consum dtc activ non-brand dtc alreadi underway
vein would expect gross-to-net spread roughli
clinic commerci setback relat ingrezza product
neurocrin focus therapi neurolog endocrin diseas
ep disc
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
 quarterli annual incom statement
million except ep
mileston licens fee
sale
incom loss tax
expens total product sale
sale
gener administr
proprietari piper jaffray juli
current disclosur inform compani found http //www piperjaffray com/researchdisclosur
